HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial
The DOI matches its Crossref record.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In phase 1 and 2 studies in patients with MASLD or MASH, liver fat reductions have been greatest with GLP-1/GIP/GCG triple agonists, GLP-1/GCG dual agonists and FGF21 analogs.”
From Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024) · cites this paper as [9]
In the citing paper
“The GLP-1/GIP/GCG triple agonist, efocipegtrutide, demonstrated up to 81% liver fat reduction after 12 weeks in participants with MASLD9.”
From Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024) · cites this paper as [9]
Citations
Cited by
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423
“6,25 Furthermore, retatrutide might increase lipolysis in adipose tissue through GIP receptor activation.”
BackgroundSanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03018-2 · Cited by 315
“On the basis of cell culture studies, retatrutide is less potent than endogenous ligands of the human GCG and GLP-1 receptors (0.3 and 0.4 times as active, respectively) and is more potent at the human GIP receptor (by a factor of 8.9) 11 .”
BackgroundInfluentialTargher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121
NASH drug treatment development: challenges and lessons
Tilg, H., Byrne, C. D., & Targher, G. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00159-0 · Cited by 81
The molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
“body weight in obese subjects with non-alcoholic fatty liver disease, and is currently in phase II trials for the targeted treatment of non-alcoholic steatohepatitis (Abdelmalek et al., 2021; Lafferty et al., 2021).”
Background
Metadata
- Authors
- Abdelmalek, M., Choi, J., Kim, Y., Seo, K., Hompesch, M., & Baek, S.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 73
- Pages
- S124
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W4233941527
- Semantic Scholar
- 0a0a9d93e6bcd1996a891a545ed2ab8965220c43
- Cited by
- 30
- References
- 0
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 2 · 2021: 4 · 2020: 1
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Journal of Hepatology (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- non-alcoholic fatty liver disease, liver fat reduction, weight loss, obesity, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0168-8278(20)30765-0
- The paper
- Abdelmalek, M., Choi, J., Kim, Y., Seo, K., Hompesch, M., & Baek, S. (2020). HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(20)30765-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.